

Amendments to the Claims:

The following listing of claims replaces all prior versions and listings of the claims in this application.

Listing of the Claims:

1. – 20. (Cancelled).

21. (New) A method for estimating the risk for development of carcinoma in a human being exposed to human papilloma virus(es) (HPV), comprising

(i) determining normalized amounts of two or more HPV groups and/or types in a sample from said human being using quantitative nucleic acid amplification of said HPV groups and/or types, wherein said determining comprises normalizing results of the quantitative nucleic acid amplification for the amount of cells sampled; and

(ii) estimating a combined risk for carcinoma development for said human being from individual risk estimation curves of the respective two or more HPV groups and/or types, wherein each individual risk estimation curve is a function of the respective normalized amount.

22. (New) A method according to claim 21, wherein the quantitative nucleic acid amplification is PCR amplification.

23. (New) A method according to claim 21, wherein the two or more HPV groups and/or types are selected from the group consisting of HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 67 and 68, and combinations thereof.

24. (New) A method according to claim 21, wherein the two or more HPV groups and/or types are selected from the group consisting of HPV 16, 18, 31, 33, 35, 39, 45, 52 and 58, and combinations thereof.

25. (New) A method according to claim 21, wherein the individual risk estimation curves provide odds ratio (OR), relative risk (RR) and/or positive predictive values (PPV).

26. (New) A method according to claim 21, wherein the human being is a woman and the carcinoma is cervical carcinoma in situ (CIS).

27. (New) A method according to claim 22, wherein the two or more HPV groups and/or types are selected from the group consisting of HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 67 and 68, and combinations thereof.

28. (New) A method according to claim 22, wherein the two or more HPV groups and/or types are selected from the group consisting of HPV 16, 18, 31, 33, 35, 39, 45, 52 and 58, and combinations thereof.

29. (New) A method according to claim 22, wherein the individual risk estimation curves provide odds ratio (OR), relative risk (RR) and/or positive predictive values (PPV).

30. (New) A method according to claim 23, wherein the individual risk estimation curves provide odds ratio (OR), relative risk (RR) and/or positive predictive values (PPV).

31. (New) A method according to claim 24, wherein the individual risk estimation curves provide odds ratio (OR), relative risk (RR) and/or positive predictive values (PPV).

32. (New) A method according to claim 22, wherein the human being is a woman and the carcinoma is cervical carcinoma in situ (CIS).

33. (New) A method according to claim 23, wherein the human being is a woman and the carcinoma is cervical carcinoma in situ (CIS).

34. (New) A method according to claim 24, wherein the human being is a woman and the carcinoma is cervical carcinoma in situ (CIS).

35. (New) A method according to claim 25, wherein the human being is a woman and the carcinoma is cervical carcinoma in situ (CIS).